Decoding the activators and effectors of IL-6 in cardiac lipotoxicity during HFD-induced obesity will provide cues for treatment of obesity-associated dyslipidemia and cardiac lipotoxicity, and improve development of novel drug therapies. The gene discussed is IL6; the disease is obesity due to melanocortin 4 receptor deficiency.